Terrance D Barrett

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. pmc Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction
    T D Barrett
    Johnson and Johnson Pharmaceutical Research and Development, L L C, San Diego, CA, USA
    Br J Pharmacol 153:1650-8. 2008
  2. ncbi request reprint Mechanism of tissue-selective drug action in the cardiovascular system
    Terrance D Barrett
    Department of Physiological Systems, Johnson and Johnson Pharmaceutical Research and Development L L C, San Diego, CA, USA
    Mol Interv 5:84-93. 2005
  3. ncbi request reprint Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity
    Kelly McClure
    Johnson and Johnson Pharmaceutical Research and Development L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 16:72-6. 2006
  4. doi request reprint Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis
    Mark D Rosen
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Drug Discover, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem 16:3917-25. 2008
  5. doi request reprint JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability
    Magda F Morton
    Johnson and Johnson Pharmaceutical Research and Development, LLC San Diego, California 92101, USA
    J Pharmacol Exp Ther 338:328-36. 2011
  6. ncbi request reprint SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists
    Laurent Gomez
    Johnson and Johnson Pharmaceutical Research and Development L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 17:6493-8. 2007
  7. doi request reprint Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase
    Mark D Rosen
    Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, CA 92121, United States
    Bioorg Med Chem Lett 19:6548-51. 2009
  8. doi request reprint Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy
    Marna Pippel
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 19:6376-8. 2009
  9. ncbi request reprint 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide
    Magda F Morton
    Johnson and Johnson Pharmaceutical Research and Development L L C, San Diego, California 92121, USA
    J Pharmacol Exp Ther 323:562-9. 2007
  10. ncbi request reprint Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands
    Craig R Woods
    Johnson and Johnson Pharmaceutical Research and Development, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 17:6905-9. 2007

Collaborators

Detail Information

Publications20

  1. pmc Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction
    T D Barrett
    Johnson and Johnson Pharmaceutical Research and Development, L L C, San Diego, CA, USA
    Br J Pharmacol 153:1650-8. 2008
    ..However, it is not clear to what extent this occurs in the early stages of pancreatitis induced by biliary tract obstruction in the rat and whether CCK initiates an inflammatory cascade in this condition...
  2. ncbi request reprint Mechanism of tissue-selective drug action in the cardiovascular system
    Terrance D Barrett
    Department of Physiological Systems, Johnson and Johnson Pharmaceutical Research and Development L L C, San Diego, CA, USA
    Mol Interv 5:84-93. 2005
    ..The third model system discusses the mechanisms through which phosphodiesterase-5 (PDE5) inhibitors act selectively to facilitate penile erection while having little effect in the non-penile vasculature that also expresses PDE5...
  3. ncbi request reprint Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity
    Kelly McClure
    Johnson and Johnson Pharmaceutical Research and Development L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 16:72-6. 2006
    ..This use of additive QSAR modeling in conjunction with combinatorial libraries represents a unique approach to the evaluation of SAR interactions between the variables of any combinatorial matrix...
  4. doi request reprint Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis
    Mark D Rosen
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Drug Discover, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem 16:3917-25. 2008
    ....
  5. doi request reprint JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability
    Magda F Morton
    Johnson and Johnson Pharmaceutical Research and Development, LLC San Diego, California 92101, USA
    J Pharmacol Exp Ther 338:328-36. 2011
    ..5 and 0.26 μM, respectively. Overall, we have demonstrated that JNJ-26070109 is a high-affinity, selective CCK2 receptor antagonist with good pharmacokinetic properties...
  6. ncbi request reprint SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists
    Laurent Gomez
    Johnson and Johnson Pharmaceutical Research and Development L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 17:6493-8. 2007
    ..The difference in affinity between the two enantiomers for the CCK(1) receptor and the flexible nature of the linker led to the design of constrained analogs with increased potency...
  7. doi request reprint Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase
    Mark D Rosen
    Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, CA 92121, United States
    Bioorg Med Chem Lett 19:6548-51. 2009
    ..The synthesis, structure-activity relationship profile, and in-vitro pharmacological characterization of this inaugural series of HRI kinase inhibitors are detailed...
  8. doi request reprint Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy
    Marna Pippel
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 19:6376-8. 2009
    ....
  9. ncbi request reprint 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide
    Magda F Morton
    Johnson and Johnson Pharmaceutical Research and Development L L C, San Diego, California 92121, USA
    J Pharmacol Exp Ther 323:562-9. 2007
    ..0 +/- 0.5 h and a very high bioavailability (108 +/- 10%) in this species. Overall, we have demonstrated that JNJ-17156516 is a high-affinity selective human CCK1 receptor antagonist with good pharmacokinetic properties in rats...
  10. ncbi request reprint Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands
    Craig R Woods
    Johnson and Johnson Pharmaceutical Research and Development, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 17:6905-9. 2007
    ..The synthesis was used to produce >100 compounds containing various functional groups, highlighting the general applicability of this strategy and to address specific metabolism issues in our CCK-2 program...
  11. doi request reprint Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor
    Terrance D Barrett
    Cardiovascular Metabolic Research, Johnson and Johnson Pharmaceutical Research and Development LLC, 3210 Merryfield Row, San Diego, CA 92121, USA
    Mol Pharmacol 79:910-20. 2011
    ..The results demonstrate that JNJ-42041935 is a new pharmacological tool, which can be used to investigate PHD inhibition and demonstrate that PHD inhibitors offer great promise for the treatment of inflammation-induced anemia...
  12. doi request reprint Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases
    Kimon C Kanelakis
    Department of Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development L L C, San Diego, California, USA
    J Biomol Screen 14:627-35. 2009
    ....
  13. ncbi request reprint Pyrazole CCK(1) receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity
    Clark Sehon
    Johnson and Johnson Pharmaceutical Research and Development L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 16:77-80. 2006
    ..Here, we disclose the synthesis of combinatorial libraries by solid-phase synthesis on Kenner 'safety catch' resin. Additive QSAR models were used to determine a lack of consistent additive SAR within the matrix...
  14. doi request reprint Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer
    Magda Morton
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Trends Pharmacol Sci 32:201-5. 2011
    ..In this paper, we discuss the contribution of gastrin to these disease pathologies and the data generated to date from clinical studies investigating CCK2 receptor antagonists...
  15. ncbi request reprint A novel, quantitative bio-assay for cholecystokinin type-1 receptor activity in the anaesthetised rat
    Jamie M Freedman
    Physiological Systems, Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    J Pharmacol Toxicol Methods 54:36-41. 2006
    ..We found that they did not provide robust pharmacokinetic-pharmacodynamic data for profiling compounds acting at these receptors. Accordingly, here we describe a novel rat duodenal contractility assay that addresses these problems...
  16. ncbi request reprint Obestatin reduces food intake and suppresses body weight gain in rodents
    Guy J Lagaud
    Internal Medicine, Johnson and Johnson Pharmaceutical Research and Development L L C, San Diego, CA 92121, USA
    Biochem Biophys Res Commun 357:264-9. 2007
    ..These findings may explain the difficulties in reproducing the effects of obestatin on feeding reported by some groups...
  17. ncbi request reprint Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis
    Ting Ting Hong
    Department of Pharmacology, University of Michigan Medical School, 1150 W Medical Center Drive, Ann Arbor, MI 48109 0632, USA
    Am J Physiol Heart Circ Physiol 294:H145-55. 2008
    ....
  18. ncbi request reprint Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation
    Bertrand Plouvier
    Cardiome Pharma Corporation, 6190 Agronomy Road, 6th Floor, Vancouver, British Columbia V6T 1Z3
    J Med Chem 50:2818-41. 2007
    ....
  19. ncbi request reprint Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel
    Peter S Fischbach
    Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI 48109 0204, USA
    J Pharmacol Exp Ther 309:554-9. 2004
    ..The findings suggest that caution should be exercised when developing compounds aimed at inducing IP, and nonspecific opening of the K-ATP channel should be avoided...
  20. pmc Tedisamil and lidocaine enhance each other's antiarrhythmic activity against ischaemia-induced arrhythmias in rats
    Guilda Sarraf
    Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Vancouver, Canada
    Br J Pharmacol 139:1389-98. 2003
    ..e., action potential-prolonging activity and inactivated state sodium channel blockade)...